We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Transfusion Protocols Compared After Cardiac Surgery

By LabMedica International staff writers
Posted on 25 Mar 2015
Unnecessary blood transfusions may increase healthcare costs both directly, because blood is an increasingly scarce and expensive resource, and indirectly due to the complications associated with transfusion.

Cardiac surgery patients who receive blood transfusions are believed to have more complications such as infections, heart attacks and strokes, and this has led to speculation that avoidance of transfusion will improve clinical outcomes.

A team of scientists led by those at the University of Bristol (UK) and those at Nuffield Department of Population Health (Oxford, UK) recruited patients over 16 years of age undergoing non-emergency cardiac surgery to the clinical trial at 17 UK hospitals. More...
Participants with a hemoglobin (Hb) level of less than 9 g/dL after their operations were randomized to have a transfusion either when they became substantially anemic (transfuse when Hb is “low,” i.e., less than 7.5 g/dL) or straightaway, when they were mildly anemic (transfuse when Hb is “high,” i.e., less than 9 g/dL).

To compare the two transfusion strategies the medical team counted the number of patients who had a serious infection, stroke, heart attack, gut or kidney failure during the first three months after the operation. The trial analyzed information for 2,003 participants, about four times more than the next largest similar trial of low and high thresholds for transfusion in patients having heart surgery.

The scientists found almost all the patients in the “high” group had a blood transfusion (92%) whereas just over half of the patients in the “low” group had a blood transfusion (53%). Slightly more patients had one or more of the serious complications listed above in the “low” group (35%) than the “high” group (33%). Moreover, more patients died in the “low” group (4.2%) than the “high” group (2.6%). This latter finding is clearly very important but it is difficult to interpret because the trial was not primarily designed to compare the difference in the number of deaths. The restrictive threshold was not superior to the liberal threshold with respect to postoperative morbidity or total costs.

Barnaby C Reeves, DPhil, MSc, MFPHM, a professor and lead author of the study, said, “Although only a hypothesis, the suggestion that it might be better rather than worse to transfuse patients who are only mildly anemic goes against the evidence about when to transfuse in non-cardiac surgery settings. Transfusing more rather than fewer patients would create a challenge for hospitals. With an aging population and possibly an increase in heart disease, obesity and diabetes, it can only become more difficult in the future to maintain the national blood supply in the UK and in other developed countries around the world. Our findings emphasize the importance of interventions to reduce blood loss in the first place.” The study was published on March 12, 2015, in the New England Journal of Medicine (NEJM).

Related Links:

University of Bristol
Nuffield Department of Population Health



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gold Member
POCT RT-qPCR Analyzer
BG-X6
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.